Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

IF ANY ENTITY WANTS THE PHARMACEUTICAL WORLD MARKET, THE USA MARKET IS STILL PART OF IT ———————
The United States was the largest pharmaceutical market in 2019, generating roughly 45 percent of total revenues worldwide. China established itself as the second-largest market with a sales share of 8.5 percent.

https://www.statista.com/statistics/245473/market-share-of-the-leading-10-global-pharmaceutical-markets/

WHY IS DR JAVITT LOOKING BEYOND COVID-19??? (...a long-term, shelf-stable formulation will be needed for ongoing use of ZYESAMI) THAT’S THE JOB OF RELIEF UNLESS THEY BOTH CONCUR ON THE WAY FORWARD...??? ————————

“We are excited that ZYESAMI has demonstrated a highly significant reduction in time to hospital discharge for seriously ill COVID-19 patients treated with High Flow Nasal Oxygen, along with an increased likelihood of recovery and excellent safety,” said Jonathan C. Javitt, M.D., M.P.H., CEO of NeuroRx. “Although our current production methods yield a drug that is sufficiently stable for emergency use, a long-term, shelf-stable formulation will be needed for ongoing use of ZYESAMI, once the pandemic subsides. The thin-film freezing technology holds great promise in potentially making this available to patients with other stages of COVID-19 with an inhaled form of ZYESAMI.”

https://www.businesswire.com/news/home/20210309005660/en/NeuroRX-and-TFF-Pharmaceuticals-Announce-Entering-Into-Feasibility-Collaboration

RELIEF NEEDS A SMOOTH OPERATOR/CREW TO NAVIGATE THE CHOPPY FDA SEAS

Early in the Covid-19 pandemic, a research and development (R&D) consultant at Swiss pharma company Relief Therapeutics, Yves Sagot, realised that a drug developed in the early 2000s for acute respiratory distress and other lung diseases and acquired by Biogen could be effective at treating Covid-19.
Relief then reached out to US-based NeuroRx to help them co-develop this drug for Covid-19, because the latter has a “history of taking already known molecules and moving them very quickly through the FDA”, explains NeuroRx CEO and chairman Professor Jonathan Javitt.
The drug in question is now called RLF-100 and is a patented formulation of aviptadil, which is a synthetic human vasoactive intestinal polypeptide (VIP). This short peptide “protects the lung from all sorts of injuries”, explains Javitt. “We now know that this peptide is extremely effective in protecting the cell that is attacked by the SARS-CoV-2 virus that causes Covid-19.”

https://www.pharmaceutical-technology.com/features/neurorx-covid-19-respiratory-failure/

ANY CHANCE OF A MERGER, BEYOND COVID-19 EUA???